<?xml version="1.0" encoding="utf-8"?>
<html madcap:lastblockdepth="4" madcap:lastheight="878" madcap:lastwidth="701" xmlns:madcap="http://www.madcapsoftware.com/Schemas/MadCap.xsd">
 <head>
 </head>
 <body>
  <h1>
   Laboratorio Reig Jofre, S.A.
  </h1>
  <div style="display: none;">
   <table cellspacing="1" class="TableStyle-dnb_tablestyle_1" style="mc-table-style: url('../Resources/TableStyles/dnb_tablestyle_1.css');">
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <thead>
     <tr class="TableStyle-dnb_tablestyle_1-Head-Header1">
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       DUNS
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       Hoovers ID
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadD-Column1-Header1">
       Tier
      </th>
     </tr>
    </thead>
    <tbody>
     <tr class="TableStyle-dnb_tablestyle_1-Body-Body1">
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
        477794820
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
       123041
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyA-Column1-Body1" style="text-align: center;">
       2
      </td>
     </tr>
    </tbody>
   </table></div><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Synopsis.flsnp" /><p>
   Laboratorio Reig Jofre (formerly Natraceutical) is shooting for your food dollar. It is the biotechnology arm of Spanish agri-chemical and food producer
   <company id="114356">
    Natra
   </company>
   (which owns about 50% of it). Through its majority stake in France's
   <company id="161566">
    Naturex
   </company>
   , the company extracts essential oils and natural chemicals from plants for use in the food production, nutritional supplements and pharmaceutical industries. The company also makes antibiotics and injectable and freeze-dried products. The Nutritional Supplements unit develops and distributes food supplements in capsules, tablets, and vials under the Forté Pharma brand. Reig Jofre sells its products throughout Europe.
  </p><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Operations.flsnp" />
  <p>
   Reig Jofre's three business units are technological specialization products, the largest segment at around 50% of total sales, nutritional supplements and consumer healthcare (28%), and therapeutic specialization products (22%).
  </p>
  <p>
   Specialized technology products include antibiotics and injectable and freeze-dried products. The specialty therapeutic division supplies products with applications in dermatology, gynecology and respiratory medicine. Nutritional supplements and consumer healthcare partners with start-ups and research centers to develop molecular products.
  </p>
  <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Geographic Reach.flsnp" />
  <p>
   Based in Barcelona, Spain, Reig Jofre has operations in 58 countries and on 5 continents. It has production facilities in Spain (Barcelona and Toledo) and Sweden, and a logistic center in Toledo. It also has sales offices in Spain, France, Belgium, Sweden, the UK, Portugal, the US and Singapore.
  </p>
  <p>
   Spain is the largest market at around 41% of revenue. The rest of Europe brings in 49% (including France 16% and the UK 9%). The rest of the world brings in the remaining 10%.
  </p>
  <p>
   Sales and Marketing
  </p>
  <p>
   Reig Jofre has a direct sales network of more than 105 people in eight countries.
  </p>
  <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Financial Performance.flsnp" />
  <p>
   <em>
    Note: Growth rates may differ after conversion to US Dollars.
   </em>
  </p>
  <p>
   In 2015, revenue grew impressively, notching up 371% growth on prior year to €156.9 due to an increase in specialized technology services due to higher sales in antibiotics, and injectable and lyophilized products.
  </p>
  <p>
   Net income saw a similar increase, up 279% to €8.7 million due to higher net sales and exchange differences.
  </p>
  <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Strategy.flsnp" />
  <p>
   Reig Jofre aims to grow through geographic expansion and putting new products to market.
  </p>
  <p>
   The company entered seven new markets in 2015, including Iraq, Ukraine and Zambia. Via a partnership with Kern Pharma, the company expanded its presence in the Japanese market.
  </p>
  <p>
   It escalated R&amp;D investment in 2015, spending €8.8 million on new products in the year, versus €4.5 in 2014. The company developed Nife-Par, the world's first liquid oral treatment for delaying pre-term labor.
  </p>
  <p>
   Reig Jofre merged with Natraceutical, a Spanish listed leader in the French nutritional supplements market, in 2014, but the two de-merged the following year.
  </p>
  <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Mergers and Acquisitions.flsnp" />
  <p>
   In 2016, the company acquired Chiesi España, a sodium heparin company. This acquisition expands the company's presence in Spain and expected to increase revenue by €0.75 million in 2016.
  </p>
 <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /></body>
</html>
